Cataract+anterior macular membrane
Conditions
Interventions
Trial group:All subjects underwent macular membrane removal and vitrectomy using Unity VCS system and 27G 30K cutting head+All subjects underwent cataract phacoemulsification using the Unity VCS syste
Sponsors
Hainan Optometry and Ophthalmology Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age range of 50-75 years old, gender not limited; 2. Diagnosis meets the following conditions (according to the staging criteria of optical coherence tomography proposed by Govetto et al.): (1) Stage 3-4 idiopathic macular membrane, planned to undergo vitreoretinal surgery without the need for intraocular filling; (2) Phase 3: The disappearance of the macular fovea and the appearance of continuous ectopic inner limiting membrane layer (EIFL), but the structure of each layer of the retina is still clear and distinguishable; (3) Stage 4: disappearance of macular fovea, appearance of ectopic inner limiting membrane layer (EIFL), and structural disorder of various layers of the retina; 3. Combining age-related cataracts, evaluated by the attending surgeon to require cataract surgery; 4. No previous history of retinal or vitreous surgery; 5. I have signed the informed consent form and agree to participate in this study and comply with all research procedures and requirements.
Exclusion criteria
Exclusion criteria: 1. Subjects who are found to have retinal tears, retinal detachment, or other retinal lesions during preoperative screening and require vitrectomy with gas or silicone oil intraocular filling; 2. Secondary macular membrane; 3. Combination of glaucoma, high intraocular pressure (>21 mmHg), optic nerve atrophy, high myopia (+3.0 D), posterior staphyloma, or other retinal diseases sensitive to fluctuations in intraocular pressure; 4. History of eye trauma, eye inflammation, previous eye surgery, eye infection, or significant eye lesions such as corneal opacity that may affect surgical procedures; 5.There are serious systemic diseases, including uncontrolled diabetes (glycosylated hemoglobin HbA1c >8.0%).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average total vitrectomy time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Average core vitrectomy time;Average peripheral vitrectomy time;Accumulated dissipated energy (CDE);Energy dissipated within the eye (phacoemulsification energy, unit: J); | — |
Countries
China
Contacts
Public ContactWang Zhaoyang
Hainan Optometry and Ophthalmology Hospital
Outcome results
None listed